ENLIVEN THERAPEUTICS, INC. Research and Development Expense
ENLIVEN THERAPEUTICS, INC. (ELVN) reported Research and Development Expense of $29.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- ENLIVEN THERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $29.00M, a 34.92% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $20.69M, a 16.90% decline year-over-year.
- ENLIVEN THERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $21.25M, a 2.51% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $18.23M, a 14.27% decline year-over-year.
- ENLIVEN THERAPEUTICS, INC. research and development expense for fiscal 2025 was $85.86M, a 6.29% increase from fiscal 2024.
- ENLIVEN THERAPEUTICS, INC. research and development expense for fiscal 2024 was $80.78M, a 25.09% increase from fiscal 2023.
- ENLIVEN THERAPEUTICS, INC. research and development expense for fiscal 2023 was $64.57M, a 108.16% increase from fiscal 2022.
- ENLIVEN THERAPEUTICS, INC. research and development expense for fiscal 2022 was $31.02M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $29.00M 10-Q · filed 2026-08-05 | $49.68M 10-Q · filed 2026-08-05 | $70.93M derived: sum of 3 quarters · filed 2026-08-05 | $89.15M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $20.69M 10-Q · filed 2026-05-07 | $41.93M derived: sum of 2 quarters · filed 2026-05-07 | $60.16M derived: sum of 3 quarters · filed 2026-05-07 | $81.65M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $21.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $39.47M derived: sum of 2 quarters · filed 2026-03-03 | $60.96M derived: sum of 3 quarters · filed 2026-08-05 | $85.86M 10-K · filed 2026-03-03 | ||||
| 2025-09-30 | $18.23M 10-Q · filed 2025-11-12 | $39.72M derived: sum of 2 quarters · filed 2026-08-05 | $64.61M 10-Q · filed 2025-11-12 | $85.33M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $21.49M 10-Q · filed 2026-08-05 | $46.39M 10-Q · filed 2026-08-05 | $67.11M derived: sum of 3 quarters · filed 2026-08-05 | $88.37M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $24.89M 10-Q · filed 2026-05-07 | $45.62M derived: sum of 2 quarters · filed 2026-05-07 | $66.88M derived: sum of 3 quarters · filed 2026-05-07 | $85.70M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $20.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $41.98M derived: sum of 2 quarters · filed 2026-03-03 | $60.81M derived: sum of 3 quarters · filed 2026-03-03 | $80.78M 10-K · filed 2026-03-03 | ||||
| 2024-09-30 | $21.26M 10-Q · filed 2025-11-12 | $40.08M derived: sum of 2 quarters · filed 2025-11-12 | $60.05M 10-Q · filed 2025-11-12 | $77.96M derived: sum of 4 quarters · filed 2025-11-12 | ||||
| 2024-06-30 | $18.83M 10-Q · filed 2025-08-13 | $38.80M 10-Q · filed 2025-08-13 | $56.70M derived: sum of 3 quarters · filed 2025-08-13 | $76.31M derived: sum of 4 quarters · filed 2025-08-13 | ||||
| 2024-03-31 | $19.97M 10-Q · filed 2025-05-14 | $37.88M derived: sum of 2 quarters · filed 2025-05-14 | $57.48M derived: sum of 3 quarters · filed 2025-05-14 | $72.66M derived: sum of 4 quarters · filed 2025-05-14 | ||||
| 2023-12-31 | $17.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $37.51M derived: sum of 2 quarters · filed 2025-03-13 | $52.69M derived: sum of 3 quarters · filed 2025-03-13 | $64.57M 10-K · filed 2025-03-13 | ||||
| 2023-09-30 | $19.61M 10-Q · filed 2024-11-13 | $34.79M derived: sum of 2 quarters · filed 2024-11-13 | $46.67M 10-Q · filed 2024-11-13 | $54.87M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $15.18M 10-Q · filed 2024-08-13 | $27.06M 10-Q · filed 2024-08-13 | $35.26M derived: sum of 3 quarters · filed 2024-08-13 | $43.09M derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | $11.88M 10-Q · filed 2024-05-14 | $20.08M derived: sum of 2 quarters · filed 2024-05-14 | $27.91M derived: sum of 3 quarters · filed 2024-05-14 | $35.84M derived: sum of 4 quarters · filed 2024-05-14 | ||||
| 2022-12-31 | $8.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $16.03M derived: sum of 2 quarters · filed 2024-03-14 | $23.96M derived: sum of 3 quarters · filed 2024-03-14 | $31.02M 10-K · filed 2024-03-14 | $18.94M 10-K · filed 2023-02-10 | |||
| 2022-09-30 | $7.83M 10-Q · filed 2023-11-09 | $182.00K 10-Q · filed 2022-10-25 | $15.77M derived: sum of 2 quarters · filed 2023-11-09 | $22.82M 10-Q · filed 2023-11-09 | $18.76M 10-Q · filed 2022-10-25 | $15.71M derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $7.94M 10-Q · filed 2023-08-10 | $7.41M 10-Q · filed 2022-08-03 | $15.00M 10-Q · filed 2023-08-10 | $18.58M 10-Q · filed 2022-08-03 | $7.88M derived: sum of 3 quarters · filed 2023-08-10 | $18.28M derived: sum of 4 quarters · filed 2023-08-10 | ||
| 2022-03-31 | $7.06M 10-Q · filed 2023-05-11 | $11.17M 10-Q · filed 2022-05-06 | -$53.00K derived: sum of 2 quarters · filed 2023-06-23 | $10.34M derived: sum of 3 quarters · filed 2023-06-23 | $20.42M derived: sum of 4 quarters · filed 2023-06-23 | |||
| 2021-12-31 | -$7.11M derived: 8-K 12 month − 10-Q 9 month · filed 2023-06-23 | $3.29M derived: sum of 2 quarters · filed 2023-06-23 | $13.36M derived: sum of 3 quarters · filed 2023-06-23 | $20.47M 8-K · filed 2023-06-23 | $38.44M 10-K · filed 2022-03-15 | |||
| 2021-09-30 | $10.40M 10-Q · filed 2022-10-25 | $20.47M derived: sum of 2 quarters · filed 2022-10-25 | $27.59M 10-Q · filed 2022-10-25 | $36.55M derived: sum of 4 quarters · filed 2022-10-25 | ||||
| 2021-06-30 | $10.07M 10-Q · filed 2022-08-03 | $17.19M 10-Q · filed 2022-08-03 | $26.15M derived: sum of 3 quarters · filed 2022-08-03 | $35.68M derived: sum of 4 quarters · filed 2022-08-03 | ||||
| 2021-03-31 | $7.12M 10-Q · filed 2022-05-06 | $16.07M derived: sum of 2 quarters · filed 2022-05-06 | $25.61M derived: sum of 3 quarters · filed 2022-05-06 | $33.48M derived: sum of 4 quarters · filed 2022-05-06 | ||||
| 2020-12-31 | $8.96M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $18.49M derived: sum of 2 quarters · filed 2022-03-15 | $26.36M derived: sum of 3 quarters · filed 2022-03-15 | $32.15M 10-K · filed 2022-03-15 | ||||
| 2020-09-30 | $9.53M 10-Q · filed 2021-11-09 | $17.40M derived: sum of 2 quarters · filed 2021-11-09 | $23.20M 10-Q · filed 2021-11-09 | $29.14M derived: sum of 4 quarters · filed 2021-11-09 | ||||
| 2020-06-30 | $7.87M 10-Q · filed 2021-08-06 | $13.66M 10-Q · filed 2021-08-06 | $19.60M derived: sum of 3 quarters · filed 2021-08-06 | $24.75M derived: sum of 4 quarters · filed 2021-08-06 | ||||
| 2020-03-31 | $5.79M 10-Q · filed 2021-05-11 | $11.73M derived: sum of 2 quarters · filed 2021-05-11 | $16.88M derived: sum of 3 quarters · filed 2021-05-11 | $21.24M derived: sum of 4 quarters · filed 2021-05-11 | ||||
| 2019-12-31 | $5.94M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-05 | $11.08M derived: sum of 2 quarters · filed 2021-03-05 | $15.45M derived: sum of 3 quarters · filed 2021-03-05 | $19.01M 10-K · filed 2021-03-05 | ||||
| 2019-09-30 | $5.14M 10-Q · filed 2020-11-05 | $9.51M derived: sum of 2 quarters · filed 2020-11-05 | $13.07M 10-Q · filed 2020-11-05 | |||||
| 2019-06-30 | $4.37M 10-Q · filed 2020-08-14 | $7.93M 10-Q · filed 2020-08-14 | ||||||
| 2019-03-31 | $3.56M 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |